[go: up one dir, main page]

CN1622811A - 烷基磷酸胆碱在预防性治疗原生动物疾病中的应用 - Google Patents

烷基磷酸胆碱在预防性治疗原生动物疾病中的应用 Download PDF

Info

Publication number
CN1622811A
CN1622811A CNA038027062A CN03802706A CN1622811A CN 1622811 A CN1622811 A CN 1622811A CN A038027062 A CNA038027062 A CN A038027062A CN 03802706 A CN03802706 A CN 03802706A CN 1622811 A CN1622811 A CN 1622811A
Authority
CN
China
Prior art keywords
active component
application
miltefosine
leishmaniasis
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038027062A
Other languages
English (en)
Chinese (zh)
Inventor
J·恩格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Publication of CN1622811A publication Critical patent/CN1622811A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA038027062A 2002-01-25 2003-01-07 烷基磷酸胆碱在预防性治疗原生动物疾病中的应用 Pending CN1622811A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10203195.9 2002-01-25
DE10203195A DE10203195A1 (de) 2002-01-25 2002-01-25 Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen

Publications (1)

Publication Number Publication Date
CN1622811A true CN1622811A (zh) 2005-06-01

Family

ID=7713213

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038027062A Pending CN1622811A (zh) 2002-01-25 2003-01-07 烷基磷酸胆碱在预防性治疗原生动物疾病中的应用

Country Status (16)

Country Link
EP (1) EP1467742A1 (es)
JP (1) JP2005515244A (es)
CN (1) CN1622811A (es)
AR (1) AR038224A1 (es)
AU (1) AU2003236787B2 (es)
BR (1) BR0307021A (es)
CA (1) CA2470185A1 (es)
CO (1) CO5601024A2 (es)
DE (1) DE10203195A1 (es)
IL (2) IL162492A0 (es)
MX (1) MXPA04007193A (es)
NZ (1) NZ548040A (es)
PE (1) PE20030732A1 (es)
TW (1) TWI339582B (es)
WO (1) WO2003061669A1 (es)
ZA (1) ZA200404690B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT501545B1 (de) * 2005-02-23 2007-10-15 Obwaller Andreas Dr Reinigungsmittel für kontaktlinsen
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
CA2632449A1 (en) * 2005-12-19 2007-06-28 Aeterna Zentaris Gmbh Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
DE4132345A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Ether-lysolecithine und alkylphosphocholine in liposomen
EP0634927B1 (en) * 1992-03-06 2001-07-04 Lica Pharmaceuticals A/S Treatment and prophylaxis of diseases caused by parasites, or bacteria
EP1051159B1 (en) * 1998-01-22 2002-04-10 Zentaris AG Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
DE10020812C2 (de) * 2000-04-20 2003-06-26 Robert Koch Inst Verwendung von Naphthindazol-4,9-chinonen als Antiparasitika
AU2002232400A1 (en) * 2000-11-06 2002-05-15 U.S. Army Medical Research And Materiel Command Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法

Also Published As

Publication number Publication date
CA2470185A1 (en) 2003-07-31
PE20030732A1 (es) 2003-09-27
DE10203195A1 (de) 2003-08-07
WO2003061669A1 (de) 2003-07-31
NZ548040A (en) 2007-06-29
JP2005515244A (ja) 2005-05-26
AR038224A1 (es) 2005-01-05
AU2003236787B2 (en) 2007-03-22
MXPA04007193A (es) 2004-10-29
IL162492A0 (en) 2005-11-20
TWI339582B (en) 2011-04-01
TW200302103A (en) 2003-08-01
ZA200404690B (en) 2004-09-27
CO5601024A2 (es) 2006-01-31
BR0307021A (pt) 2004-11-03
EP1467742A1 (de) 2004-10-20
IL162492A (en) 2009-12-24

Similar Documents

Publication Publication Date Title
US6943155B2 (en) Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity
CN1188422C (zh) 钙(3s)四氢－3－呋喃基(1s,2r)－3－[[(4－氨基苯基)磺酰基](异丁基)氨基]－1－苯甲基－2－(膦酰氧基]丙基氨基甲酸酯
RS53466B (sr) Upotreba amisulprida za tretiranje postoperativne mučnine i povraćanja
CN100413492C (zh) 口服给药治疗利什曼病的含有米替福星的固体药物组合物
JP2010501538A (ja) 固形剤型
CN1622811A (zh) 烷基磷酸胆碱在预防性治疗原生动物疾病中的应用
US7887817B2 (en) Process for preventing protozoal diseases
CN1302780C (zh) 烷基胆碱磷酸在制备用抗肿瘤药之前和/或期间治疗肿瘤的药物中的应用
AU8424091A (en) Pharmaceutical compositions containing 5-difluoromethoxy-2-{(3,4-dimethoxy-2-pyridyl) methylsulfinyl} benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
HK1077217A (en) Use of alkylphosphocholines for the preventative treatment of protozoan diseases
JPWO2019234240A5 (es)
JP6771274B2 (ja) 内服用組成物
JPS6140205B2 (es)
JP2009508834A (ja) ビスホスホネート製剤
CN1921866A (zh) 使用雷洛昔芬和阿伦膦酸盐的改善的联合治疗
CN1883503A (zh) 用于治疗胃病的含有抗溃疡药和粘膜保护剂的药物组合物
HK1033434A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
HK1061978A1 (en) Lipid peroxide-lowering compositions
HK1061978B (en) Lipid peroxide-lowering compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077217

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050601

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077217

Country of ref document: HK